Clinical outcomes and reintervention after endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis in absence of cholangitis
Indian Journal of Gastroenterology · 2024
DOI: 10.1007/s12664-024-01630-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Gastroenterology, 2024. Verfasst von Ryosuke Horio und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8670, Japan. Hauptthemen laut MEDLINE: Cholangiopancreatography, Endoscopic Retrograde, Cholangitis, Sclerosing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aim Endoscopic retrograde cholangiopancreatography (ERCP) may help detect cholangiocarcinoma in patients with primary sclerosing cholangitis (PSC), but it may be associated with complications. This study was aimed at determining the prognostic impact of ERCP on patients with PSC without cholangitis.
Methods
Patients with PSC without cholangitis were divided into two groups: those who underwent ERCP within three years after diagnosis (ERCP-performed group) and those who did not (non-ERCP group). These groups were compared in terms of clinical outcomes (liver-related death or liver transplantation, endoscopic treatment requirement and repeated cholangitis) and the composite outcome.
Results
Of 99 patients with PSC with detailed medical history, 49 were included in the ERCP-performed group and 21 in the non-ERCP group. In Kaplan-Meier analysis, the non-ERCP group was less likely to achieve the three outcomes and the composite outcome, showing statistical significance (endoscopic treatment requirement; p = 0.017 and composite outcome; p = 0.014). A Cox proportional hazards model indicated that ERCP in the asymptomatic state was a significant predictor of endoscopic treatment requirement (hazard ratio [HR]: 4.37, 95% confidence interval [CI]: 1.03–18.59) and the composite outcome (HR: 4.54, 95% CI: 1.07–19.28).
Conclusion
ERCP in patients with PSC without cholangitis is likely to require further endoscopic treatment and may be associated with poor prognosis. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8670, Japan.
- Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8670, Japan. kato.jun@chiba-u.jp.
ORCID-Profile: Jun Kato
Zitieren
APA
Horio, R., Kato, J., Taida, T., Ohta, Y., Saito, K., Oyama, Y., Nakazawa, H., Mamiya, Y., Goto, C., Takahashi, S., Ouchi, M., Kurosugi, A., Sonoda, M., Kan, M., Kaneko, T., Nagashima, H., Akizue, N., Takahashi, K., Okimoto, K., …, & Kato, N. (2024). Clinical outcomes and reintervention after endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis in absence of cholangitis. Indian Journal of Gastroenterology. https://doi.org/10.1007/s12664-024-01630-1
Vancouver
Horio R, Kato J, Taida T, Ohta Y, Saito K, Oyama Y, et al. Clinical outcomes and reintervention after endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis in absence of cholangitis. Indian Journal of Gastroenterology. 2024. doi:10.1007/s12664-024-01630-1
BibTeX
@article{Horio2024,
author = {Horio, Ryosuke and Kato, Jun and Taida, Takashi and Ohta, Yuki and Saito, Keiko and Oyama, Yuhei and Nakazawa, Hayato and Mamiya, Yukiyo and Goto, Chihiro and Takahashi, Satsuki and Ouchi, Mayu and Kurosugi, Akane and Sonoda, Michiko and Kan, Motoyasu and Kaneko, Tatsuya and Nagashima, Hiroki and Akizue, Naoki and Takahashi, Koji and Okimoto, Kenichiro and Ohyama, Hiroshi and Matsumura, Tomoaki and Ohno, Izumi and Kato, Naoya},
title = {Clinical outcomes and reintervention after endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis in absence of cholangitis},
journal = {Indian Journal of Gastroenterology},
year = {2024},
doi = {10.1007/s12664-024-01630-1}
}
EUVIMED